Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Astrazeneca (AZNCF) Receivables (2016 - 2025)

Historic Receivables for Astrazeneca (AZNCF) over the last 17 years, with Q4 2025 value amounting to $15.2 billion.

  • Astrazeneca's Receivables rose 430.21% to $15.2 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $15.2 billion, marking a year-over-year increase of 430.21%. This contributed to the annual value of $15.2 billion for FY2025, which is 430.21% up from last year.
  • Per Astrazeneca's latest filing, its Receivables stood at $15.2 billion for Q4 2025, which was up 430.21% from $14.3 billion recorded in Q3 2025.
  • Over the past 5 years, Astrazeneca's Receivables peaked at $15.2 billion during Q4 2025, and registered a low of $6.3 billion during Q1 2021.
  • For the 5-year period, Astrazeneca's Receivables averaged around $11.2 billion, with its median value being $11.2 billion (2023).
  • In the last 5 years, Astrazeneca's Receivables skyrocketed by 11261.51% in 2021 and then crashed by 40.57% in 2024.
  • Quarter analysis of 5 years shows Astrazeneca's Receivables stood at $11.5 billion in 2021, then rose by 6.36% to $12.2 billion in 2022, then increased by 13.01% to $13.8 billion in 2023, then rose by 5.71% to $14.6 billion in 2024, then increased by 4.3% to $15.2 billion in 2025.
  • Its Receivables was $15.2 billion in Q4 2025, compared to $14.3 billion in Q3 2025 and $14.2 billion in Q2 2025.